ANS-858 functions as a reversible, orally bioavailable inhibitor designed to modulate ALDH2, an enzyme identified by researchers as a key regulator of craving in both alcohol and substance use disorders. CEO Brent Blackburn stated that the drug builds on human genetic evidence linking reduced ALDH2 activity to lower alcohol consumption, aiming to translate this biological foundation into a once-daily therapeutic option.

Beyond substance use, the company is exploring the broader utility of its ALDH2 platform. Amygdala is investigating whether the mechanism can mitigate compulsive food cravings in obesity and binge eating disorders, potentially serving as a standalone treatment or an adjunct to GLP-1 receptor agonists. The firm is also testing its proprietary library of inhibitors in precision oncology, targeting colorectal cancers that harbor APC mutations. With the FDA’s go-ahead, the company will now focus on clinical execution to validate its platform, which has previously received backing from NIH grants and the ABMRF/Foundation for Alcohol Research.